GUGGENHIME ANDREW 4

What Happened

• Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte (PCVX), exercised 10,000 vested options on July 6, 2026 at $5.35 per share (cost $53,500) and sold 10,000 shares the same day in two open-market transactions for a combined proceeds of $572,836. The sales were executed under a Rule 10b5-1 trading plan adopted March 4, 2026. An additional derivative line in the filing shows 10,000 shares disposed at $0.00 and a footnote indicates shares are held by ALG 2025 GRAT HOLDINGS LLC (see Key Details).

Key Details

• Transaction date: 2026-07-06.
• Exercise: 10,000 shares @ $5.35 = $53,500 (option fully vested per footnote).
• Sales: 7,913 shares @ weighted-average $57.16 = $452,283 (prices ranged $56.595–$57.59); 2,087 shares @ weighted-average $57.76 = $120,553 (prices ranged $57.61–$58.32). Total proceeds ≈ $572,836.
• Net cash after exercise (proceeds minus exercise cost): ≈ $519,336.
• Footnotes: sales effected under a 10b5-1 plan (F1); weighted-average pricing with price ranges provided on-file (F2, F3); shares referenced as held by ALG 2025 GRAT HOLDINGS LLC, owned by a grantor retained annuity trust with the reporting person as annuitant/trustee (F4); option fully vested and exercisable (F5).
• Shares owned after the transaction: not disclosed in the provided filing.
• Filing timeliness: no late filing indicated in the provided data.

Context

• This was effectively a same-day exercise-and-sell (cashless) transaction: options were exercised and the resulting shares were sold on the same date. Sales executed under a 10b5-1 plan are pre-arranged and typically occur regardless of short-term market moves. For retail investors, purchases or exercises can signal insider confidence, but same-day sales under a trading plan are often used for liquidity or tax-management and are not a direct indicator of sentiment.